AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

18 Mar 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

01 Mar 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

26 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

25 Feb 2021 06:00:02 By Nasdaq GlobeNewswire

Agios to Present at March Investor Conferences

23 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

11 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

26 Jan 2021 15:01:00 By Nasdaq GlobeNewswire

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

17 Jan 2021 09:00:00 By Nasdaq GlobeNewswire

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

11 Jan 2021 06:00:01 By Nasdaq GlobeNewswire